Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Anne Yeakey"'
Autor:
Frances Priddy, Spyros Chalkias, Brandon Essink, Jordan Whatley, Adam Brosz, Ivan T. Lee, Jing Feng, LaRee Tracy, Weiping Deng, Wen Zhou, Honghong Zhou, Avika Dixit, Sabine Schnyder-Ghamloush, Bethany Girard, Elizabeth de Windt, Anne Yeakey, Jacqueline Miller, Rituparna Das, Barbara J. Kuter
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 862-878 (2024)
Introduction Vaccination against SARS-CoV-2 is an integral pillar of the public health approach to COVID-19. With the emergence of variants of concern that increase transmissibility and escape from vaccine- or infection-induced protection, vaccines h
Externí odkaz:
https://doaj.org/article/342872b428b143008da0ffc3a2845735
Autor:
Amparo L. Figueroa, Kashif Ali, Gary Berman, Honghong Zhou, Weiping Deng, Wenqin Xu, Stephanie Lussier, Bethany Girard, Frank J. Dutko, Karen Slobod, Anne Yeakey, Frances Priddy, Jacqueline M. Miller, Rituparna Das
Publikováno v:
EClinicalMedicine, Vol 74, Iss , Pp 102720- (2024)
Summary: Background: Longitudinal changes in vaccination-induced immune response remain inadequately characterized in adolescents. We present long-term safety, immunogenicity, and COVID-19 incidence following a 2-dose mRNA-1273 100-μg primary series
Externí odkaz:
https://doaj.org/article/6f2192f297bc4ef6ab25ef446fac3250
Autor:
Simon de Lusignan, Filipa Ferreira, Silvia Damaso, Rachel Byford, Sameera Pathirannehelage, Anne Yeakey, Ivelina Yonova, Anne Schuind, Gael Dos Santos
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 5, Pp 1048-1059 (2019)
Influenza is a major public health burden, mainly prevented by vaccination. Recommendations on influenza vaccine composition are updated annually and constant benefit-risk monitoring is therefore needed. We conducted near-real-time enhanced passive s
Externí odkaz:
https://doaj.org/article/1df4a41b29a14fb1b299d3e1173bcb67
Autor:
Oscar Della Pasqua, Nancy Skoura, Vijayalakshmi Chandrasekaran, Helen C. Steel, Anne Yeakey, William B. Smith, Jie Wang-Jairaj, Julia Billiard, Lionel Tan
Publikováno v:
The Lancet Infectious Diseases. 20:983-991
Summary Background Raxibacumab is a monoclonal antibody against protective antigen, which is the cell-binding part of Bacillus anthracis toxin, and is approved for treatment and postexposure prophylaxis of inhalational anthrax. Anthrax Vaccine Adsorb
Autor:
Alexander C. Schmidt, Gael Dos Santos, Tamara Eckermann, Xavier Martínez-Gómez, Vishvesh Shende, Ignacio Salamanca de la Cueva, Lode Godderis, Hugo Loos, Bach-Yen Nguyen, Silvia Damaso, Anne Yeakey
Publikováno v:
Drug Safety
INTRODUCTION: Seasonal influenza causes numerous deaths worldwide each year. Annual vaccination for disease prevention is crucial. Seasonal vaccines are updated each year to closely match circulating strains. OBJECTIVE: To comply with European Medici
Autor:
David J. Figueroa, Danae Williams, Saad Z. Usmani, Aránzazu Alonso Alonso, Anne Yeakey, Chang-Ki Min, Brandon E. Kremer, Ira Gupta, Wojciech Janowski, Morrys C. Kaisermann, Hang Quach, Geraldine Ferron-Brady, Lukasz M. Mis, Youngil Koh, Xiaoou L. Zhou, Andreas Guenther
Publikováno v:
Blood. 138:2738-2738
Introduction: The bortezomib, lenalidomide, and dexamethasone (VRd) regimen is an acceptable standard of care (SoC) for both transplant-eligible and transplant-ineligible newly diagnosed multiple myeloma (TI NDMM). Ongoing development of novel therap
Autor:
Monique C. Minnema, Ellie Im, Frank G. Basile, Brandon E. Kremer, L. Mary Smith, Paul G. Richardson, Katarina Uttervall, Kevin W. Song, Paula Rodriguez-Otero, Hang Quach, Ajay K. Nooka, Ira Gupta, Herbert Struemper, Christoph M. Ahlers, Anne Yeakey, Morrys Kaisermann, Beata Holkova, Nicola Jackson, Suzanne Trudel, Natalie S. Callander, Rocio Montes de Oca
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S156
Background Single-agent belamaf, a B-cell maturation antigen-targeting antibody-drug conjugate, induced durable responses with a manageable safety profile in patients with RRMM at 13 months of follow-up (DREAMM-2; NCT03525678). The unique multimodal
Autor:
Ryan Ramaekers, Mala K. Talekar, Keith Stockerl-Goldstein, Bradley Augustson, Bikramjit Chopra, Rocio Montes de Oca, Deborah A. Smith, Rafat Abonour, Geraldine Ferron-Brady, Andrew Spencer, Jacqueline Davidge, Maria-Victoria Mateos, Amit Khot, Ajay K. Nooka, Brandon E. Kremer, Cindy Lee, Rachel Rogers, Adam Forbes, Rakesh Popat, Ira Gupta, Anne Yeakey, Hang Quach
Publikováno v:
Blood. 136:19-20
Introduction: Single-agent belamaf (GSK2857916), a B-cell maturation antigen-targeting antibody-drug conjugate, demonstrated deep and durable responses with a manageable safety profile in patients with heavily pretreated RRMM (median 7 lines of prior
Autor:
Anne Yeakey, Paul G. Richardson, Chris Shelton, David Routledge, Ajay K. Nooka, Hareth Nahi, Suzanne Trudel, Hang Quach, Brandon E. Kremer, Kevin W. Song, Rocio Montes de Oca, Elaine M. Paul, Josephine Khan, Paula Rodriguez-Otero, Beata Holkova, Sofia Paul, Maria Brouch, Geraldine Ferron-Brady, Ira Gupta, Ellie Im, L. Mary Smith, Christoph M. Ahlers
Publikováno v:
Blood. 136:1-2
Introduction: Single-agent belamaf (GSK2857916), a B-cell maturation antigen-targeting antibody-drug conjugate, induced deep and durable responses in patients with RRMM, with a manageable safety profile with 13 months of follow-up (DREAMM-2; NCT03525
Publikováno v:
Advances in Therapy
Introduction Influenza is an important cause of morbidity and mortality in Europe. Prevention by annual vaccination is most effective but with yearly vaccine reformulation to match circulating virus strains, vaccine safety must be continuously monito